The increase in international awareness has led to the establishment of various partnerships:

  • Dr Chris Jones, Institute of Cancer Research Sutton, UK – gene-expression profiling/array CGH.
  • Dr Darren Hargrave, Great Ormond Street Hospital for Children, London, UK – general DIPG.
  • Dr. Jacques Grill / Stéphanie Puget, Institute Gustave Roussy Villejuif, France – exchange of biopsy tissue and cell lines.
  • Dr. Rintaro Hashizume, University of California San Francisco, USA – cell line exchange.
  • Dr. Stefaan W. van Gool, KU Leuven, Belgium – application of E98 model for immunotherapy.
  • Dr. Marike L. D. Broekman, ErasmusMC, Rotterdam – application of E98 model for virotherapy.
  • “Cure starts now” foundation, consisting of different laboratories situated in North America: Maryam Fouladi (Cincinnati), Charles Keller (Portland, Oregon), Oren Becher (Duke University Durham), Michelle Monje (Palo Alto), Cynthia Hawkins (Toronto), Xiao-Nan Li (Baylor College, Houston).

New written projects, some of which have generated additional funding (including support from KIKA for the continued development of the animal model):

  • Convection-enhanced delivery of the cytotoxin GB-13 for the treatment of diffuse pontine glioma in orthotopic mouse models. Targetpeutics, Inc* (active).
  • Towards novel therapeutics for the treatment of diffuse pontine glioma (DIPG) – EDLI Foundation: granted (€ 50.000,-).
  • Development of in vitro and in vivo mouse models for diffuse pontine glioma (DIPG) – KiKa: granted (€ 269.500,-).
  • Unravelling diffuse pontine glioma (DIPG) – Complete Genomics, $ 80.000,- (active).

The Semmy Foundation is still the sole sponsor of experimental scientific research. Only when that produces results will other funds offer their support. Much remains to be done!